BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 17443678)

  • 1. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
    Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
    Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study.
    Kuhle S; Lau A; Bajzar L; Vegh P; Halton J; Cherrick I; Anderson R; Desai S; McCusker P; Wu J; Abshire T; Mahoney D; Mitchell L
    Br J Haematol; 2006 Sep; 134(5):526-31. PubMed ID: 16856890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
    Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
    Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment.
    Harlev D; Zaidman I; Sarig G; Ben Arush MW; Brenner B; Elhasid R
    Thromb Res; 2010 Aug; 126(2):93-7. PubMed ID: 20546854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.
    Giordano P; Molinari AC; Del Vecchio GC; Saracco P; Russo G; Altomare M; Perutelli P; Crescenzio N; Santoro N; Marchetti M; De Mattia D; Falanga A
    Am J Hematol; 2010 May; 85(5):325-30. PubMed ID: 20425794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
    Ruud E; Holmstrøm H; de Lange C; Natvig S; Albertsen BK; Wesenberg F
    Pediatr Hematol Oncol; 2006; 23(3):207-16. PubMed ID: 16517537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
    Mauz-Körholz C; Junker R; Göbel U; Nowak-Göttl U
    Thromb Haemost; 2000 Jun; 83(6):840-3. PubMed ID: 10896235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
    Athale UH; Siciliano SA; Crowther M; Barr RD; Chan AK
    Br J Haematol; 2005 Jun; 129(6):803-10. PubMed ID: 15953008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
    Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
    BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
    Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
    Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparin in pediatric patients.
    Sutor AH; Chan AK; Massicotte P
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():31-9. PubMed ID: 15085464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
    Cohen H; Bielorai B; Harats D; Toren A; Pinhas-Hamiel O
    Pediatr Blood Cancer; 2010 May; 54(5):703-6. PubMed ID: 20063421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.
    Greiner J; Schrappe M; Claviez A; Zimmermann M; Niemeyer C; Kolb R; Eberl W; Berthold F; Bergsträsser E; Gnekow A; Lassay E; Vorwerk P; Lauten M; Sauerbrey A; Rischewski J; Beilken A; Henze G; Korte W; Möricke A;
    Haematologica; 2019 Apr; 104(4):756-765. PubMed ID: 30262570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and meta-analysis of the effectiveness of primary thromboprophylaxis in acute lymphoblastic leukemia during early-phase therapy including asparaginase or its prolonged form.
    Hu Z; Persaud Y; Ahuja S
    Crit Rev Oncol Hematol; 2024 May; 197():104347. PubMed ID: 38583546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
    Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
    Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment.
    Mitchell LG; Sutor AH; Andrew M
    Semin Thromb Hemost; 1995; 21(4):390-401. PubMed ID: 8747702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment.
    Nowak-Göttl U; Kenet G; Mitchell LG
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):103-14. PubMed ID: 19285277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
    Lejhancova-Tousovska K; Zapletal O; Vytiskova S; Strbackova P; Sterba J
    Blood Coagul Fibrinolysis; 2012 Mar; 23(2):144-54. PubMed ID: 22227959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.